ASRT Quote, Financials, Valuation and Earnings

Altimmune, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of -380280%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Altimmune, Inc.'s return on equity of -56.24%.

Assertio Holdings, Inc. has a consensus price target of $39.94, signalling upside risk potential of 236.46%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.67 which suggests that it could grow by 296.11%. Given that Altimmune, Inc. has higher upside potential than Assertio Holdings, Inc., analysts believe Altimmune, Inc. is more attractive than Assertio Holdings, Inc..

Assertio Holdings, Inc. has a beta of 0.775, which suggesting that the stock is 22.468% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of 0.091, suggesting its less volatile than the S&P 500 by 90.87%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Altimmune, Inc. quarterly revenues of $5K. Assertio Holdings, Inc.'s net income of $11.4M is higher than Altimmune, Inc.'s net income of -$19M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 4.42x versus 17,712.00x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Actinium Pharmaceuticals, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of -5701.11%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Actinium Pharmaceuticals, Inc.'s return on equity of -133.63%.

Assertio Holdings, Inc. has a consensus price target of $39.94, signalling upside risk potential of 236.46%. On the other hand Actinium Pharmaceuticals, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 380.77%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Assertio Holdings, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Assertio Holdings, Inc..

Assertio Holdings, Inc. has a beta of 0.775, which suggesting that the stock is 22.468% less volatile than S&P 500. In comparison Actinium Pharmaceuticals, Inc. has a beta of -0.303, suggesting its less volatile than the S&P 500 by 130.29%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Actinium Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Actinium Pharmaceuticals, Inc. quarterly revenues of $90K. Assertio Holdings, Inc.'s net income of $11.4M is higher than Actinium Pharmaceuticals, Inc.'s net income of -$5.1M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Actinium Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 4.42x versus 360.49x for Actinium Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of -62.32%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Ultragenyx Pharmaceutical, Inc.'s return on equity of -566.4%.

Assertio Holdings, Inc. has a consensus price target of $39.94, signalling upside risk potential of 236.46%. On the other hand Ultragenyx Pharmaceutical, Inc. has an analysts' consensus of $56.55 which suggests that it could grow by 176.53%. Given that Assertio Holdings, Inc. has higher upside potential than Ultragenyx Pharmaceutical, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Ultragenyx Pharmaceutical, Inc..

Assertio Holdings, Inc. has a beta of 0.775, which suggesting that the stock is 22.468% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical, Inc. has a beta of 0.161, suggesting its less volatile than the S&P 500 by 83.893%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are smaller than Ultragenyx Pharmaceutical, Inc. quarterly revenues of $207M. Assertio Holdings, Inc.'s net income of $11.4M is higher than Ultragenyx Pharmaceutical, Inc.'s net income of -$129M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Ultragenyx Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 4.42x versus 3.00x for Ultragenyx Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of -876.34%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Verastem, Inc.'s return on equity of -1773.4%.

Assertio Holdings, Inc. has a consensus price target of $39.94, signalling upside risk potential of 236.46%. On the other hand Verastem, Inc. has an analysts' consensus of $16.63 which suggests that it could grow by 191.16%. Given that Assertio Holdings, Inc. has higher upside potential than Verastem, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Verastem, Inc..

Assertio Holdings, Inc. has a beta of 0.775, which suggesting that the stock is 22.468% less volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.56%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Verastem, Inc. quarterly revenues of $11.2M. Assertio Holdings, Inc.'s net income of $11.4M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 4.42x versus 26.68x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.